Atezolizumab and Bevacizumab for Mucosal Melanoma
Author Information
Author(s): Jie Dai, Tianxiao Xu, Lifeng Li, Meiyu Fang, Jing Lin, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Jun Guo, Yu Chen, Lili Mao, Lu Si
Primary Institution: Peking University Cancer Hospital and Institute
Hypothesis
The combination of atezolizumab and bevacizumab will improve survival outcomes in patients with unresectable or metastatic mucosal melanoma.
Conclusion
The study confirms the sustained efficacy of atezolizumab combined with bevacizumab in patients with advanced mucosal melanoma, with specific predictors of response identified.
Supporting Evidence
- The median overall survival was 23.7 months.
- The 3-year overall survival rate was 28.7%.
- Patients with upper site melanoma had longer progression-free survival.
- NRAS mutations were associated with enhanced angiogenesis.
- Inflammatory cell infiltration may be a prognostic indicator.
Takeaway
This study shows that a combination of two drugs can help people with a serious type of skin cancer live longer and feel better.
Methodology
Patients received intravenous atezolizumab and bevacizumab every 3 weeks, with multi-omics analyses performed on available samples.
Potential Biases
Potential biases may arise from the observational nature of the study and the limited sample size.
Limitations
The sample size was limited, and the study may have statistical and biological complexities due to multiple comparisons.
Participant Demographics
Patients with unresectable or metastatic mucosal melanoma, with a median follow-up of 40.3 months.
Statistical Information
P-Value
p=0.003
Confidence Interval
95% CI, 15.1–34
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website